Company profile

Ascentage Pharma Group Inc.

AAPG

Share price · AAPG

$18.20-0.36 (-1.94%) 3M

close as of 2026-08-18 · 24h delayed · vol 7K

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento

Assets

(5 total)
5Total Assets
0Approved
1Phase 3 / Filed
4Phase 1–2 / Early
4Diseases
Quick filter:
Showing 5 of 5 assets
Target & Modality
APG-2575(Lisaftoclax )
Phase 3
BCL-2Small molecule
Acute Myeloid LeukemiaMultiple MyelomaSystemic Lupus Erythematosus
APG-115
Phase 2
MDM2
Acute Myeloid Leukemia
Olverembatinib
Phase 2
BCR-ABL (also AKT, c-Kit, ERK)
Acute Myeloid Leukemia
APG-1252
Phase 1
Bcl-2 / Bcl-xLSmall molecule
Non-Small Cell Lung Cancer
APG-2449
Phase 1
FAK / ALK / ROS1Small molecule
Non-Small Cell Lung Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Insider transactions

Research

Unlock insider transactions

Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.

Institutional holders

Research

Unlock institutional holders

Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.